255 related articles for article (PubMed ID: 19325240)
61. Ascorbyl free radical reflects catalytically active iron after intravenous iron saccharate injection.
Stefánsson BV; Haraldsson B; Nilsson U
Free Radic Biol Med; 2008 Nov; 45(9):1302-7. PubMed ID: 18775775
[TBL] [Abstract][Full Text] [Related]
62. Absorption of iron dextran from the peritoneal cavity of rats.
Suzuki K; Twardowski ZJ; Nolph KD; Khanna R; Moore HL
Adv Perit Dial; 1995; 11():57-9. PubMed ID: 8534738
[TBL] [Abstract][Full Text] [Related]
63. Intravenous iron-gluconate during haemodialysis modifies plasma beta2-microglobulin properties and levels.
Michelis R; Sela S; Kristal B
Nephrol Dial Transplant; 2005 Sep; 20(9):1963-9. PubMed ID: 15956071
[TBL] [Abstract][Full Text] [Related]
64. Peritoneal protein losses in diabetic patients starting peritoneal dialysis: is there a relationship with diabetic vascular lesions?
Coronel F; Cigarrán S; Herrero JA; Delgado J; Ramos F; Gomis A
Adv Perit Dial; 2009; 25():115-8. PubMed ID: 19886331
[TBL] [Abstract][Full Text] [Related]
65. Estimate the insulin absorption in diabetic patients on peritoneal dialysis.
Pantsulaia T; Chokhonelidze I; Lomitashvili T
Georgian Med News; 2006 Nov; (140):28-30. PubMed ID: 17179582
[TBL] [Abstract][Full Text] [Related]
66. [Influence of different pharmacological agents in the ex vivo proliferation of mesothelial cells obtained from the peritoneal effluent of patients treated with peritoneal dialysis].
Castro MA; Bajo MA; del Peso G; Larrocha C; Castro MJ; Sánchez-Tomero JA; Cirugeda A; Aguilera A; Alvarez V; Costero O; Vara F; Fernández-Chacón JL; Selgas R
Nefrologia; 2003; 23(3):243-51. PubMed ID: 12891939
[TBL] [Abstract][Full Text] [Related]
67. [Effects of peritoneal dialysis solution on proliferation and apoptosis of rat peritoneal mesothelial cells].
Chen SX; Ren H; Liu ZR; Liu HF
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Sep; 26(9):1276-9. PubMed ID: 16982434
[TBL] [Abstract][Full Text] [Related]
68. Whole-body protein turnover in peritoneal dialysis patients: a comparison of the [15N]glycine end product and the [13C]leucine precursor methods.
Tjiong HL; Swart R; Rietveld T; Wattimena JL; Hop WC; Fieren MW; van den Berg JW
Nephrol Dial Transplant; 2008 Aug; 23(8):2660-5. PubMed ID: 18308773
[TBL] [Abstract][Full Text] [Related]
69. L-2-oxothiazolidine-4-carboxylic acids slow down dialysate-induced senescence in human peritoneal mesothelial cells.
Sosinska-Zawierucha P; Mackowiak B; Begier-Krasinska B; Hoppe K; Breborowicz A
J Physiol Pharmacol; 2018 Dec; 69(6):. PubMed ID: 30802216
[TBL] [Abstract][Full Text] [Related]
70. The cellular contribution to effluent potassium and its relation to free water transport during peritoneal dialysis.
Coester AM; Struijk DG; Smit W; de Waart DR; Krediet RT
Nephrol Dial Transplant; 2007 Dec; 22(12):3593-600. PubMed ID: 17664179
[TBL] [Abstract][Full Text] [Related]
71. The relationship between bone morphogenic protein-7 and peritoneal transport characteristics.
Szeto CC; Chow KM; Kwan BC; Lai KB; Chung KY; Leung CB; Li PK
Nephrol Dial Transplant; 2008 Sep; 23(9):2989-94. PubMed ID: 18400816
[TBL] [Abstract][Full Text] [Related]
72. Effects of everolimus as an antiproliferative agent on regression of encapsulating peritoneal sclerosis in a rat model.
Duman S; Bozkurt D; Sipahi S; Sezak M; Ozkan S; Ertilav M; Sen S; Ok E
Adv Perit Dial; 2008; 24():104-10. PubMed ID: 18986012
[TBL] [Abstract][Full Text] [Related]
73. Effect of iron sucrose on human peritoneal mesothelial cells.
Breborowicz M; Polubinska A; Tam P; Wu G; Breborowicz A
Eur J Clin Invest; 2003 Dec; 33(12):1038-44. PubMed ID: 14636286
[TBL] [Abstract][Full Text] [Related]
74. Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease.
Sinha S; Chiu DY; Peebles G; Kolakkat S; Lamerton E; Fenwick S; Kalra PA
J Ren Care; 2009 Jun; 35(2):67-73. PubMed ID: 19432851
[TBL] [Abstract][Full Text] [Related]
75. Intravenous iron increases labile serum iron but does not impair forearm blood flow reactivity in dialysis patients.
Schaller G; Scheiber-Mojdehkar B; Wolzt M; Puttinger H; Mittermayer F; Hörl WH; Födinger M; Sunder-Plassmann G; Vychytil A
Kidney Int; 2005 Dec; 68(6):2814-22. PubMed ID: 16316358
[TBL] [Abstract][Full Text] [Related]
76. Cytokines and other soluble factors in dialysate -- indicators of altered peritoneal function?
Martikainen TA; Ekstrand AV; Teppo AM; Honkanen EO; Grönhagen-Riska C
Scand J Urol Nephrol; 2002; 36(6):450-4. PubMed ID: 12623511
[TBL] [Abstract][Full Text] [Related]
77. A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome.
Grote L; Leissner L; Hedner J; Ulfberg J
Mov Disord; 2009 Jul; 24(10):1445-52. PubMed ID: 19489063
[TBL] [Abstract][Full Text] [Related]
78. Synthesis of hyaluronic acid by human peritoneal mesothelial cells: effect of cytokines and dialysate.
Breborowicz A; Korybalska K; Grzybowski A; Wieczorowska-Tobis K; Martis L; Oreopoulos DG
Perit Dial Int; 1996; 16(4):374-8. PubMed ID: 8863330
[TBL] [Abstract][Full Text] [Related]
79. In vitro exposure to carbon dioxide induces oxidative stress in human peritoneal mesothelial cells.
Bentes de Souza AM; Wang CC; Chu CY; Briton-Jones CM; Haines CJ; Rogers MS
Hum Reprod; 2004 Jun; 19(6):1281-6. PubMed ID: 15105394
[TBL] [Abstract][Full Text] [Related]
80. Intravenous iron sucrose does not impair sonographic brachial vasodilation in peritoneal dialysis patients.
Bolaños L; González-Juanatey C; Testa A; Ranero R
Adv Perit Dial; 2008; 24():90-5. PubMed ID: 18986009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
